Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response
NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death UPLIZNA is indicated as monotherapy for
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) - read this article along with other careers information, tips and advice on BioSpace
Separate analysis being presented at the AAN Annual Meeting shows UPLIZNA reduced pain associated with NMOSD over three years Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation
/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton s.